Core Insights - Hikma achieved significant growth in 2025, launching 84 products and becoming the largest pharmaceutical company in MENA by sales for the first time in its history [1] - The company is focusing on strengthening its injectable business and has begun implementing leadership changes to address challenges [1] Business Performance - The Branded division is recognized as a best-in-class operation in MENA, characterized by local market expertise, a broad portfolio, and strong customer relationships [2] - Hikma Rx has gained importance, focusing on growth in higher-value areas such as complex medicines and CMO services [2] Market Position - Hikma Rx is positioned as one of the leading U.S. domestic producers of generic medicines, contributing positively to the U.S. healthcare landscape [3] - The injectable segment maintains strong margins, but continued investment is necessary to sustain growth [3]

Hikma Pharma tumbles on softer guidance as buyback fails to soften pill Proactive uses images sourced from Shutterstock Hikma Pharmaceuticals PLC shares fell almost 16% to 1,390p after the drugs group delivered results for 2025 in line with forecasts but disappointed with weaker than expected guidance for 2026. Executive chair Said Darwazah will become full-time chief executive for the next two years, with current chief financial officer Khalid Nabilsi becoming deputy chief executive with responsibility f ...

Core Insights - OneSource Specialty Pharma has received approval for its generic version of Ozempic in Saudi Arabia, allowing it to enter a significant market for type-2 diabetes and weight-loss drugs [1][2] - The partnership with Hikma Pharmaceuticals PLC aims to meet the rising demand for affordable generic drug alternatives in the Middle East and North Africa (MENA) region [3][4] Company Strategy - OneSource will manufacture semaglutide at its Bengaluru facility, while Hikma will leverage its commercial reach to enhance the drug's availability [3] - The collaboration with Hikma, the largest pharmaceutical company in the MENA region by sales, is expected to provide a strong platform for scaling access to this therapy [4] Market Dynamics - OneSource is preparing for a significant increase in demand for generic semaglutide as Novo Nordisk is set to lose patent exclusivity in over 80 countries this year [5] - The company is fast-tracking a $100 million capacity expansion to capitalize on the global boom in weight-loss drugs [5] Financial Performance - In Q3, OneSource's revenue fell 26% year-over-year to ₹290.3 crore ($33.1 million) due to delays in semaglutide approvals in Canada [6] - The company's EBITDA dropped 88%, with the EBITDA margin contracting to 6% from 36% a year earlier [6] - OneSource aims to achieve $500 million in revenue by FY28 [6]

OneSource Specialty Pharma has received Saudi Food and Drug Authority (SFDA) approval for its generic Ozempic (semaglutide) in Saudi Arabia, paving the way for its commercialisation with Hikma Pharmaceuticals PLC (Hikma), their exclusive partner for the Middle East and North Africa (MENA), the company said.The approval marks OneSource’s entry—a contract development and manufacturing organisation—into Saudi Arabia, one of the largest markets for GLP-1 therapies. The partnership aims to increase access to aff ...

Core Insights - Hikma Pharmaceuticals has launched TYZAVAN, a ready-to-use vancomycin premix with room-temperature stability, aimed at improving the treatment of sepsis and other infections in a timely manner [1][3]. Product Overview - TYZAVAN is a glycopeptide antibacterial indicated for treating septicemia, infective endocarditis, skin and skin structure infections, bone infections, and lower respiratory tract infections in patients aged 1 month and older [2][21]. - The product is the only FDA-approved vancomycin injection that can be stored at room temperature, eliminating the need for compounding and accelerating treatment [3]. Market Need - Sepsis is a critical health issue in the U.S., with a diagnosis occurring every 20 seconds and a related death every two minutes. Rapid antibiotic administration is essential for improving survival rates, which decrease by 15% after 87–113 minutes [4]. Company Commitment - Hikma emphasizes its R&D capabilities in developing innovative healthcare solutions that enhance patient care, particularly in urgent situations. The company aims to streamline the administration of essential medicines [5]. Product Features - TYZAVAN offers several advantages, including: - Ready-to-use formulation that reduces preparation complexity and handling risks [6]. - Available in seven strengths (0.5g–2g) for flexible dosing [7]. - A shelf life of 16 months without refrigeration, compatible with automated dispensing systems [7].

Group 1 - The article does not provide any specific content related to a company or industry [1]

Core Insights - The exanthema market was valued at USD 1.39 billion in 2024 and is projected to grow at a CAGR of 6.10% to reach USD 2.51 billion by 2034, driven by rising viral and bacterial infections and advancements in diagnostic methods [1][13]. Market Drivers - The growth of the exanthema market is primarily driven by the increasing incidence of viral and bacterial infections, leading to skin rashes and related diseases, with notable diseases including measles, rubella, and chickenpox [2]. - Improvements in healthcare facilities and infrastructure are encouraging more individuals to seek medical care, further propelling market growth [2]. - Innovations in diagnostic methods, such as molecular testing and serological assays, are significantly boosting demand in the exanthema market [3]. Initiatives Supporting Growth - National and international organizations are launching initiatives aimed at preventing exanthema, such as the IA2030 Measles & Rubella Partnership, which includes prominent entities like the CDC and WHO, contributing to increased market demand [4]. - The emergence of outbreaks, such as the recent surge in measles cases in Romania, has heightened the urgency for effective interventions, thereby increasing the demand for treatments and vaccinations [5][6]. Regulatory Developments - New FDA approvals, such as Merck's announcement regarding the intramuscular administration of MMRV family vaccines, are expected to enhance convenience and accessibility, thereby increasing market demand [7]. Competitive Landscape - Pfizer Inc. and BioNTech SE are exploring mRNA vaccine candidates against shingles, indicating ongoing innovation and competition within the exanthema market [8]. Regional Insights - The United States is leading the exanthema market, expected to dominate due to the largest patient pool and market for treatment [10].